Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 27 for “"Systemic toxicities"”.
-
Development of Implantable Optical Fibers for Immunotherapeutics Delivery and Tumor Impedance Measurement
… but suffer from disadvantages such as severe toxicities and moderate patient-response rates. None of the current delivery strategies, including local administration aiming to avoid systemic toxicities, can sustainably supply drugs over the course of weeks; adjustment of drug dose, either to …
-
Combination Therapy With Aerosol Il-2 and Nk Cells For The Treatment of Osteosarcoma Lung Metastasis
… there was no evidence of IL-2-associated systemic toxicities. In conclusion, combining NK cell therapy with aerosol IL-2 achieved organ-specific NK cell migration and proliferation in the lung and reduced pulmonary metastatic burden, while at the same time avoided the systemic toxicities …
-
Dendrimer-Mediated Targeted Immunotherapies for the Treatment of Glioblastoma
… thereby requiring high doses that lead to systemic toxicities. Dendrimer-based nanomedicines have shown promise for targeted delivery in neuroinflammation from systemic circulation. Here, we demonstrate that hydroxyl-terminated polyamidoamine dendrimers localize specifically to …
-
Use of Systems Biology in Deciphering Mode of Action and Predicting Potentially Adverse Health Outcomes of Nanoparticle Exposure, Using Carbon Black as a Model
… they exhibit increased potential for systemic toxicities due to their deposition deep within pulmonary tissue upon inhalation. Thus, standard regulatory assays alone may not always be appropriate for evaluation of their full spectrum of toxicity. Systems biology (e.g., the study of …
-
Polypeptide-based oligonucleotide delivery systems: design, characterization, and formulation for safe and effective cancer immunotherapy
… with demonstrated antitumor activity, but systemic toxicities and inconsistent efficacy have limited their clinical development. Here, we investigated glatiramer acetate (GA), an FDA-approved lysine-rich polypeptide, as a delivery scaffold to enhance the safety and efficacy of CpG ODNs. GA …
-
Locally Administered Particle-Anchored Cytokines Safely Enhance Cancer Immunotherapy
… by severe immune-related adverse events upon systemic administration. None of the current delivery strategies can fully address issues of toxicities and sustainably supply cytokines over the course of a few days without compromising cytokines' structural integrity. Herein, we have developed a …
-
Cancer Immunotherapy: Limitations and Potential Strategies
… treatment. Chapter 2 will mainly focus on the systemic toxicities after immunotherapy that occur with age and also provide new means to limit these lethal toxicities. Chapter 3 will address the lack of proper immune activation in current immunotherapies. This will be demonstrated by the …
-
Combining the strengths of cytotoxic T cells and nanomedicines for cancer immunotherapy
… a potential risk for relapse, metastasis, and systemic toxicity. To reduce the risk of systemic toxicities, researchers have developed strategies to encapsulate chemotherapeutics in nanocarriers, aiming to improve the specific delivery of therapeutics to the tumor. Despite the success of …
-
Development of orthogonal nanotherapeutics for colorectal cancer treatment
… RG7388 and Entinostat suffer from severe systemic toxicities such as leukopenia and thrombocytopenia.<br/><br/>The emerging clinical success of nanomaterials over the last decades is offering a promising platform for the delivery of drug combinations to the tumour site while preserving the …
-
Lipid-based microbubbles for enhanced delivery of anti PD-l1
… an inflection point due to variable efficacy and systemic toxicities. A major development was the discovery of checkpoint blockade inhibition – referring to the use of antibodies that block immune-inhibitory pathways. While checkpoint inhibitors can be highly effective for cancer treatment, these …
-
Development of novel targeted drug formulations for the treatment of haematological malignancies
… of Vyxeos®, and Marqibo®, which minimised systemic toxicities and improved drug pharmacokinetics. However, antibody-targeted formulations offer even greater potential due to their high specificity. While antibody-conjugated NPs (ACNPs) are lacking clinical approval, antibody-drug conjugates …
-
Novel approaches for targeting the FGFR pathway in cancer to improve the therapeutic index
… show promise, they are limited by dose-limiting toxicities (DLT) from systemic FGFR inhibition in normal tissue, particularly hyperphosphatemia affecting 60-80% of patients due to the disruption of FGFR1-mediated phosphate homeostasis. To address these limitations, this thesis explores two …
-
Design, development and characterization of novel Globo-H-targeting CAR T cells for solid tumours cell therapy
… targets that minimize on-target, off-tumour toxicities. In this thesis, we investigated Globo-H, a glycosphingolipid antigen abundantly expressed in several epithelial cancers - particularly of the gastrointestinal tract - but minimally detected in normal tissues, making it an attractive …
-
Pharmaceutical characterization of selected xenobiotics utilizing novel drug delivery systems
… developed to mitigate poor bioavailability and systemic toxicities associated with doxorubicin. The speculated mechanism of cardiac and renal toxicities induced by doxorubicin involves oxidative stress while the mechanism behind the poor bioavailability is due to doxorubicin being a substrate of …
-
Ocular pharmacokinetics and efficacy of various amino acid and dipeptide prodrugs of ganciclovir
… with thymidine analogues are their ocular and systemic toxicities in long term usage. Even though GCV and ACV have good efficacies against HSV, their limited solubility, poor corneal absorption and diminished ocular bioavailability limits their effectiveness. Ointments and gels are also …
-
Identification of a tumor-targeting-peptide and development of a tumor-targeted-cytokine vector for systemic treatment of primary and metastatic malignancies
… less than acceptable therapeutic efficacy and toxicities, but tumor-targeting motifs can improve these effects. Both antibodies and peptides specific for tumor antigens have been used in recombinant protein and gene therapy systems to increase the intratumoral cytokine accumulation and decrease …
-
SOMATOSTATIN RECEPTOR TYPE 2 (SSTR2) FOR ADOPTIVE T CELL IMAGING, STIMULATION, AND ELIMINATION
… to maintain CAR T cell persistence without any systemic toxicities sometimes observed with ACTs.
-
Bridging gaps between in vitro and in vivo data in pulmonary aerosol delivery with focus on pharmacokinetics
… high drug levels in the blood that could lead to systemic toxicities. Besides the PK, the efficacy of Ptx-NP was investigated. The analysis of Ptx doses in different compartments of the in vitro model demonstrated a cell-association of 30% of the initial dose 24 h after the aerosolized delivery of …
-
Programming synthetic T cell immunity against solid tumors
… fully direct T cell activity without widespread systemic toxicities and overcome barriers like poor tumor infiltration, proliferation, and cytotoxicity, the ability to locally turn genes on or off is needed. This includes activation of immunostimulatory genes (e.g., chemokines, cytokines) and …
-
Development of targeted drug nanosystems using variable new antigen receptors (VNARs)
… such as paclitaxel and irinotecan, minimising systemic toxicities. NP success in the treatment of PDAC could hypothetically be enhanced through the attachment of a ligand. Though no actively targeted NP has been approved in the clinic, previous endeavours have identified the importance of …
Page 1 of 2